Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces

Birgit Jaschke1, Cornelia Michaelis, Stefan Milz

  • 1Deutsches Herzzentrum and 1. Medizinische Klinik, Technische Universität, Munich, Germany.

Cardiovascular Research
|August 23, 2005
PubMed
Abstract

Insights

Local statin delivery via drug-eluting stents effectively limits neointimal hyperplasia without harming endothelial regrowth. This offers a promising alternative to current treatments for preventing cardiac events after stenting.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Biomedical Engineering

Background:

  • Drug-eluting stents (DES) limit neointimal hyperplasia but can impair endothelial regrowth, increasing cardiac event risk.
  • Identifying agents that selectively inhibit smooth muscle cell proliferation and migration is crucial for improved DES therapy.

Purpose of the Study:

  • To evaluate cerivastatin's local effects on coronary artery smooth muscle cells (CASMC) and endothelial cells (CAEC).
  • To assess cerivastatin-eluting stents' efficacy in inhibiting neointima formation and promoting endothelial regrowth.

Main Methods:

  • In vitro assessment of cerivastatin's impact on CASMC and CAEC proliferation, migration, and cytotoxicity.
  • In vivo evaluation of cerivastatin-eluting stents in a rat carotid artery model.

Main Results:

  • Cerivastatin differentially inhibited CASMC proliferation and migration more than CAEC.
  • Therapeutic concentrations showed minimal cytotoxicity in both cell types.
  • Cerivastatin-eluting stents significantly reduced neointima formation.
  • Endothelial coverage was comparable between cerivastatin-eluting and control stents.

Conclusions:

  • Local cerivastatin delivery via DES platforms can effectively limit neointima formation.
  • Statins warrant further clinical investigation for their anti-restenotic potential.
  • Local statin administration may offer a more endothelium-friendly approach compared to current DES compounds.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...